SCHEMBL9956705

SCHEMBL9956705

Cc1ccc(-c2cn3nc(-c4ccccc4O)ccc3n2)cc1NC(=O)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 6/20 0.42
CSNK1E P49674 6/20 0.42
TTK P33981 2/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 2/20 0.39
LRRK2 Q5S007 1/20 0.39
ADORA1 P30542 2/20 0.39
RIPK1 Q13546 2/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9956160 0.91 CSNK1D (0.45) CSNK1DCSNK1ERIPK1LMNATP53
SCHEMBL9956830 0.91 RIPK1 (0.43) CSNK1DCSNK1ETTKNPC1RAB9A
SCHEMBL9955669 0.91 KDM4E (0.43) CSNK1DCSNK1ETTKMEN1KMT2A
SCHEMBL9957437 0.90 CSNK1D (0.41) CSNK1DCSNK1ETTKMAPTLRRK2
SCHEMBL9956540 0.89 MAPT (0.42) CSNK1DCSNK1EMEN1NPC1RAB9A
SCHEMBL9956448 0.89 RXFP1 (0.46) CSNK1DCSNK1ETTKMAPTRIPK1
SCHEMBL9955573 0.88 CSNK1D (0.40) CSNK1DCSNK1ETTKMAPTADORA1
SCHEMBL9956892 0.88 CSNK1D (0.45) CSNK1DCSNK1EMAPTTP53
SCHEMBL9957565 0.87 CSNK1D (0.44) CSNK1DCSNK1ETTKMAPTADORA1
SCHEMBL9956282 0.87 RIPK1 (0.44) CSNK1DCSNK1EMAPTRIPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635578-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES Hengrui (USA) Ltd. (US) 2013-09-11 EP claimed
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI (USA), LTD. 2012-07-12 US claimed
WO-2012088411-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES PAMLICO PHARMACEUTICAL INC. (US) 2012-06-28 WO claimed
EP-2635578-B1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI USA LTD (US) 2015-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES PRXL2A, CDK2, CCNA2 CSNK1D 655/4885CSNK1E 852/4885TTK 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.